The report provides market landscape, competitive landscape and market trends information on the facial aesthetics market.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
The global market for facial aesthetics is forecast to reach about $4 billion in 2017 at a compound annual growth rate (CAGR) of 9%. The growth is expected to be driven by minimally invasive and non-invasive procedures that offer long term results at competitive pricing. The Botulinum toxin market is expected to maintain the lead in terms of market share, in spite of its high side effects profile. This is due to advantages such as better patient comfort, short procedure times and faster results. Hyaluronic acid based dermal fillers are primarily driven by their low side effects profile. The results of hyaluronic acid based fillers (HA fillers) are short term (three to six months) and as a result recurring income for physicians and aesthetic centers encourages growth of this segment. The particle and polymer fillers market will register lower growth rates compared to Botulinum toxin and HA fillers. Focus of companies on lower side effects profile and longevity of aesthetic results of up to two years encourage the future growth of this segment. Loss of recurring income due to long term results discourages physicians and aesthetic centers to suggest polymer fillers for their patients. Collagen products will experience continue to experience decline in the sales as it has been the historic trend.This is due to reasons such as increasing awareness about botulinum toxin and HA fillers and their reducing price trends.
The US contribution towards the global facial aesthetics market was valued at 39% in 2009. The US facial aesthetics market is forecast to reach $1.7 billion in 2017, with a CAGR of 11%. The market is expected to be driven by the popularity of botulinum toxin and hyaluronic acid based dermal fillers used for facial rejuvenation. Inception of DYSPORT from Medicis in mid-2009 is likely to affect Allergan’s domination for botulinum toxin products in the US. The competition has also resulted in decreasing price trends in the US and as a result will encourage new patients to go for botulinum toxin procedures. The market is also expected to be driven by an increasing number of providers, such as Merz Pharmaceuticals, diversifying into botulinum toxin based products and dermal fillers. The direct to consumer marketing approach of the companies is expected to increase awareness about facial aesthetics in the US. Non-invasive dermal fillers such as hyaluronic acid formulated with anesthetic lidocaine are being predominantly used in the US, which will drive the market for facial aesthetics in the US.
Allergan Dominates the Global Facial Aesthetics Market
Allergan dominates the global facial aesthetics market with 68% of the market share in 2010. This is mainly driven by factors such as Allergan’s dominance in botulinum toxin (botox) and wide presence in all the market’s countries across
all segments. Allergan holds 80% market share in the botulinum toxin segment, while Medicis holds 16%. Medicis is expected to increase its market share in the botulinum toxin segment since its product DYSPORT is becoming popular due to its cost effectiveness and results comparable to Allergan’s BOTOX Cosmetic. Medicis has presence only in the US and has a 40% market share in hyaluronic acid based dermal fillers in the US. Q-Med AB does not have presence in the botulinum toxin segment. However Q-Med AB has a market share of 41% worldwide in the dermal fillers market, which includes HA fillers and polymer fillers. Q-Med AB is followed by Allergan with a market share of 35%. Allergan is expected to maintain its lead in terms of market share but the gap is expected to narrow due to an increasing number of providers. Increasing competition also is expected to lead to a decreasing price trend in the facial aesthetics market.
The botulinum toxin (Botox) market is forecast to reach $2.5 billion in 2017 at a CAGR of 9%. The growth in the BOTOX market is expected to be the fastest among all the segments in the facial aesthetics market. The US will continue to be the largest market for BOTOX in the future. The BOTOX market is driven by factors such as low procedure time and cost effectiveness of the procedure. Chronic facial wrinkles can be treated using botulinum toxin unlike other anti wrinkle procedures. It is the most effective non surgical anti wrinkle solution available in the facial aesthetics market. It is possible to get rid of age old facial lines and wrinkles in just five to 10 minutes while it is not the case with other procedures. Also the uniqueness of botulinum toxin is the wide spectrum of treatment that it provides. It can be used for forehead wrinkles, eyelids, lips and the neck. The results of botulinum toxin procedure are not permanent, due to which the side effects are also not permanent. This is due to the fact that the ingredients used in botulinum toxin degrade over a period of time that not only results in temporary results but also the side effects that do not last long The future market is expected to be robust with more prominent players such as Medicis and Merz Pharmaceuticals coming up with their versions of botulinum toxin at a cheaper price. In 2009, the Food and Drug Administration (FDA) had given directions to all the manufacturers of botulinum toxin to come up with a Risk Evaluation and Mitigation Strategy (REMS). This is to create more
awareness among the patients and the physicians about the risk involved in using botulinum toxin when it spreads beyond the injection site.
Focus on Permanency of Results from Facial Aesthetic Procedures with Low Side Effects Profile will Fuel Long Term Growth
Currently facial aesthetic procedures do not provide permanent results. The result lasts for a maximum time frame of two years. The longevity of the results comes with higher side effects profile. HA fillers do not have any side effects unlike botulinum toxin or particle and polymer fillers. However the results from HA fillers last from six to twelve months. Particle and polymer fillers provide results that last up to two years but with higher side effects profile. Botulinum toxin provides results that last only up to six months. This requires the patients to undergo multiple treatments that can prove to be expensive. Hence the long term growth of this market depends on the focus of companies in this market to increase the longevity of the results from facial injectables. Longevity of results should not compromise on the safety of these products. Natural results with lower side effects profile are most desired. This will significantly increase the number of patients opting for facial aesthetic procedures. Permanency of the results may affect the recurring revenue of the physicians carrying out these procedures in the short term perspective. However longevity of the results will bring effective penetration of facial aesthetic procedures.
GlobalData’s new report, “Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global facial aesthetics market. The report provides market landscape, competitive landscape and market trends information on the facial aesthetics market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts
For further details, please click or add the below link to your browser:
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782